{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:09:22Z","timestamp":1777936162501,"version":"3.51.4"},"reference-count":43,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2026]]},"DOI":"10.70352\/scrj.cr.25-0827","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:16:38Z","timestamp":1777587398000},"page":"n\/a","source":"Crossref","is-referenced-by-count":0,"title":["Pathologic Complete Response to Modified FOLFIRINOX Enabling Conversion Surgery in Pancreatic Acinar Cell Carcinoma on Hemodialysis: A Case Report"],"prefix":"10.70352","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8276-9279","authenticated-orcid":false,"given":"Kazuki","family":"Sekine","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1512-1687","authenticated-orcid":false,"given":"Yoshinori","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Irie","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihito","family":"Kotera","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Mise","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Saiura","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"51119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Park W, Chawla A, O\u2019Reilly EM. Pancreatic cancer: a review. JAMA 2021; 326: 851\u201362.","DOI":"10.1001\/jama.2021.13027"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Ide Y, Otsuka T, Shimokawa M, et al. Conversion surgery for unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel. Anticancer Res 2023; 43: 1817\u201326.","DOI":"10.21873\/anticanres.16335"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Hank T, Strobel O. Conversion surgery for advanced pancreatic cancer. J Clin Med 2019; 8: 1945.","DOI":"10.3390\/jcm8111945"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Funakoshi T, Horimatsu T, Nakamura M, et al. Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan. ESMO Open 2018; 3: e000301.","DOI":"10.1136\/esmoopen-2017-000301"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Cengiz K. Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol 2002; 33: 121\u20136.","DOI":"10.1023\/A:1014489911153"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018; 379: 2395\u2013406.","DOI":"10.1056\/NEJMoa1809775"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 2016; 388: 248\u201357.","DOI":"10.1016\/S0140-6736(16)30583-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013; 310: 1473\u201381.","DOI":"10.1001\/jama.2013.279201"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Ushida Y, Inoue Y, Oba A, et al. Optimizing indications for conversion surgery based on analysis of 454 consecutive Japanese cases with unresectable pancreatic cancer who received modified FOLFIRINOX or gemcitabine plus nab-paclitaxel: a single-center retrospective study. Ann Surg Oncol 2022; 29: 5038\u201350.","DOI":"10.1245\/s10434-022-11503-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Okano N, Kawai M, Ueno M, et al. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: a multicenter retrospective cohort study (PC-CURE-1). J Hepatobiliary Pancreat Sci 2024; 31: 816\u201329.","DOI":"10.1002\/jhbp.12066"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Nishikawa Y, Funakoshi T, Horimatsu T, et al. Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. Cancer Chemother Pharmacol 2017; 79: 629\u201333.","DOI":"10.1007\/s00280-017-3249-1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Imamaki H, Oura M, Oguro F, et al. Removal rate of 5-fluorouracil and its metabolites in patients on hemodialysis: a report of two cases of colorectal cancer patients with end-stage renal failure. Cancer Chemother Pharmacol 2024; 93: 161\u20137.","DOI":"10.1007\/s00280-023-04577-w"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Janus N, Thariat J, Boulanger H, et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 2010; 21: 1395\u2013403.","DOI":"10.1093\/annonc\/mdp598"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Pirovano M, Ganini C, Gallieni M, et al. Management of cytotoxic chemotherapy in patients undergoing dialysis: a still unresolved issue of onconephrology. J Nephrol 2025; 38: 1369\u201379.","DOI":"10.1007\/s40620-024-02102-7"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Tezuka R, Iwashita T, Uemura S, et al. The efficacy and safety of modified FOLFIRINOX for unresectable advanced pancreatic cancer in elderly versus young patients: a multicenter retrospective cohort study. Pancreatology 2022; 22: 1134\u201340.","DOI":"10.1016\/j.pan.2022.11.005"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Cavanna L, Stroppa EM, Citterio C, et al. Modified FOLFIRINOX for unresectable locally advanced\/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience. OncoTargets Ther 2019; 12: 3077\u201385.","DOI":"10.2147\/OTT.S200754"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) de Jesus VHF, Camandaroba MPG, Donadio MDS, et al. Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma. J Gastrointest Oncol 2018; 9: 694\u2013707.","DOI":"10.21037\/jgo.2018.04.02"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Stein SM, James ES, Deng Y, et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer 2016; 114: 737\u201343.","DOI":"10.1038\/bjc.2016.45"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Li X, Ma T, Zhang Q, et al. Modified-FOLFIRINOX in metastatic pancreatic cancer: a prospective study in Chinese population. Cancer Lett 2017; 406: 22\u20136.","DOI":"10.1016\/j.canlet.2017.07.012"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Vary A, Lebellec L, Di Fiore F, et al. FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma. Ther Adv Med Oncol 2021; 13: 17588359211029825.","DOI":"10.1177\/17588359211029825"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Ghorani E, Wong HH, Hewitt C, et al. Safety and efficacy of modified FOLFIRINOX for advanced pancreatic adenocarcinoma: a UK single-centre experience. Oncology 2015; 89: 281\u20137.","DOI":"10.1159\/000439171"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Ozaka M, Ishii H, Sato T, et al. A phase II study of modified FOLFIRINOX for chemotherapy-na\u00efve patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 2018; 81: 1017\u201323.","DOI":"10.1007\/s00280-018-3577-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Kang H, Jo JH, Lee HS, et al. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World J Gastrointest Oncol 2018; 10: 421\u201330.","DOI":"10.4251\/wjgo.v10.i11.421"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Ulusakarya A, Teyar N, Karabou\u00e9 A, et al. Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma. Medicine (Baltimore) 2019; 98: e15341.","DOI":"10.1097\/MD.0000000000015341"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Yoshida K, Iwashita T, Uemura S, et al. A multicenter prospective phase II study of firstline modified FOLFIRINOX for unresectable advanced pancreatic cancer. Oncotarget 2017; 8: 111346\u201355.","DOI":"10.18632\/oncotarget.22795"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Uemura S, Iwashita T, Ichikawa H, et al. The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy. Br J Nutr 2021; 125: 1140\u20137.","DOI":"10.1017\/S0007114520003463"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Lee JC, Kim JW, Ahn S, et al. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: using cumulative relative dose intensity. Eur J Cancer 2017; 76: 125\u201333.","DOI":"10.1016\/j.ejca.2017.02.010"},{"key":"28","unstructured":"28) Stoop TF, Oba A, Wu YHA, et al. Pathological complete response in patients with resected pancreatic adenocarcinoma after preoperative chemotherapy. JAMA Netw Open 2024; 7: e2417625."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Ikezawa K, Urabe M, Kai Y, et al. Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment. Jpn J Clin Oncol 2024; 54: 271\u201381.","DOI":"10.1093\/jjco\/hyad176"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Busch E, Werft W, Bougatf N, et al. Metastatic acinar cell carcinoma of the pancreas: a retrospective cohort study on systemic chemotherapy and review of the literature. Pancreas 2021; 50: 300\u20135.","DOI":"10.1097\/MPA.0000000000001765"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Distler M, R\u00fcckert F, Dittert DD, et al. Curative resection of a primarily unresectable acinar cell carcinoma of the pancreas after chemotherapy. World J Surg Oncol 2009; 7: 22.","DOI":"10.1186\/1477-7819-7-22"},{"key":"32","unstructured":"32) Yamamoto T, Ohzato H, Fukunaga M, et al. Acinar cell carcinoma of the pancreas: a possible role of S-1 as chemotherapy for acinar cell carcinoma. A case report. JOP 2012; 13: 87\u201390."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Endo S, Ohtsuka T, Mochidome N, et al. A case of pancreatic acinar cell carcinoma treated by neoadjuvant chemotherapy and subsequent resection. Jpn J Gastroenterol Surg 2013; 46: 847\u201353. (in Japanese)","DOI":"10.5833\/jjgs.2012.0342"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Jimbo M, Batista PM, Baliff JP, et al. Neoadjuvant chemotherapy and appleby procedure for pancreatic acinar cell carcinoma: a case report. Case Rep Pancreat Cancer 2016; 2: 46\u20139.","DOI":"10.1089\/crpc.2016.0009"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Villano AM, Barrak D, Jain A, et al. Robot-assisted combined pancreatectomy\/hepatectomy for metastatic pancreatic acinar cell carcinoma: case report and review of the literature. Clin J Gastroenterol 2020; 13: 973\u201380.","DOI":"10.1007\/s12328-020-01146-z"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Sunami T, Yamada A, Kondo T, et al. Exceptional response of pancreatic acinar cell carcinoma and bile duct cancer to platinum-based chemotherapy in a family with a germline BRCA2 variant. Pancreas 2022; 51: 1258\u201362.","DOI":"10.1097\/MPA.0000000000002150"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Uemura S, Maeda H, Tanioka N, et al. Successful conversion surgery after FOLFIRINOX therapy in a patient with advanced pancreatic acinar cell carcinoma with a solitary peritoneal dissemination: a case report. Cancer Rep (Hoboken) 2022; 5: e1648.","DOI":"10.1002\/cnr2.1648"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Yamada S, Motegi H, Kurihara Y, et al. A resected case of acinar cell carcinoma of the pancreas with liver metastasis following chemotherapy using modified FOLFIRINOX. Surg Case Rep 2023; 9: 147.","DOI":"10.1186\/s40792-023-01729-1"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Watanabe T, Nagaoka Y, Kimura N, et al. A case of BRCA1-mutated giant pancreatic acinar cell carcinoma successfully treated with modified FOLFIRINOX therapy and radical resection. Clin J Gastroenterol 2024; 17: 970\u20135.","DOI":"10.1007\/s12328-024-01992-1"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Sugata S, Yamaguchi A, Kamada H, et al. Metastatic pancreatic acinar cell carcinoma with BRCA2 gene alternation resected after modified FORFIRINOX therapy: a case report and literature review. J Gastrointest Oncol 2025; 16: 726\u201337.","DOI":"10.21037\/jgo-24-845"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Mandelker D, Marra A, Zheng-Lin B, et al. Genomic profiling reveals germline predisposition and homologous recombination deficiency in pancreatic acinar cell carcinoma. J Clin Oncol 2023; 41: 5151\u201362.","DOI":"10.1200\/JCO.23.00561"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Matsubayashi H, Todaka A, Tsushima T, et al. The response of pancreatic acinar cell carcinoma to platinum and olaparib therapy in a germline BRCA2 variant carrier: case report and literature review. Fam Cancer 2024; 23: 393\u20138.","DOI":"10.1007\/s10689-024-00390-3"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Emelyanova M, Pudova E, Khomich D, et al. Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes. Ther Adv Med Oncol 2022; 14: 17588359221083050.","DOI":"10.1177\/17588359221083050"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.25-0827\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:21:25Z","timestamp":1777692085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.25-0827\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.25-0827","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"cr.25-0827"}}